biostudies-literatureVolders PJOncoDNA, BelgiumBelgian Society of Medical OncologistsVelsera, USAEuropean CommissionIllumina66https://www.ebi.ac.uk/biostudies/studies/S-EPMC11893761biostudies-literatureUnknown9(1)The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days. Actionable genomic markers were identified in 81% of patients, substantially higher than the 21% using nationally reimbursed, small panels. A national molecular tumor board (nMTB) recommended treatments for 69% of patients, with 23% receiving matched therapies. Reasons for non-compliance were highly variable across clinical sites. NPJ precision oncologyA nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.PMC11893761101080009Schroder DVan Huysse JVan der Meulen JDe Greve JSchreuer MTejpar SAftimos PVan Den Bulcke MMebis JVan Dam PJVaeyens FDedeurwaerdere FDe Pauw RCanon JLVolders PJVanden Bempt IPrenen Hde Azambuja EPunie KLoontiens SCuppens KBeniuga GLambin SMaes BRutten Avan Marcke CMartens GRottey SFroyen GDecoster LfalseA nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days. Actionable genomic markers were identified in 81% of patients, substantially higher than the 21% using nationally reimbursed, small panels. A national molecular tumor board (nMTB) recommended treatments for 69% of patients, with 23% receiving matched therapies. Reasons for non-compliance were highly variable across clinical sites. 2025-01-01T00:00:00Z2025 Mar2026-06-02T19:16:51.376Z2025-04-04T02:50:38.545ZS-EPMC118937614006510610.1038/s41698-025-00858-0